Navigation Links
Mylan Announces Transition of Chief Financial Officer
Date:2/19/2009

PITTSBURGH, Feb. 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Chief Financial Officer, Edward J. Borkowski, will transition out of his role over the next several months. Borkowski will remain with Mylan until a successor is named and in place.

Mylan's Vice Chairman and CEO Robert J. Coury stated: "Not only do I want to thank Ed for the commitment he brought to Mylan over the last seven years, I want to commend him for the role he played in supporting me and Mylan during the company's transformation, especially in helping to build a very strong foundation for the company to grow and in establishing a sound and balanced capital structure. It is with both optimism and gratitude that we make this announcement today, and I am pleased that Ed will continue to direct our finance team through this transition while a new CFO is successfully recruited and on board over the next few months."

Borkowski stated: "Since I began my tenure at Mylan seven years ago, I've had the absolute pleasure to work with Robert Coury and the Mylan management team in executing the company's vision and growth strategy, which has resulted in Mylan's transformation from a U.S.-based generic drug company to a leading global provider of quality generic and specialty pharmaceuticals. We have achieved a great deal over the last several years, and I'm very proud that I've been able to complete all that was asked of me. As Mylan has entered into the next phase of executing on its global operational goals, I believe that it is an appropriate time for me to be able to move on to new challenges. Mylan is well positioned to succeed on the global stage, and I am proud to have been a part of Mylan's continued growth and leadership in the industry."

Mylan has retained the executive recruitment firm Korn/Ferry International to lead the search for Borkowski's replacement.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... As the standards ... a communications platform that positions them as the go-to thought leader in all ... online publication as an always-on, always-fresh news, views and advocacy engine, called ONS ...
(Date:3/24/2017)... ... 24, 2017 , ... Gastro Health (“GH”) ( http://www.gastrohealth.com ... for colonoscopy at the HyGIeaCare® Center that is to be located adjacent to ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration (FDA), ...
(Date:3/24/2017)... ... ... “Vintage and Harvest A Cultivation of Christian Love” is the creation of ... Carolina with his wife, Anna Marie. He and his wife are the proud parents ... the author of “Shadow and Substance.” , “Love, the agape kind, is seen as ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF ... the greater Houston Area. The new location is located at 2255 E. Mossy Oaks ... Springwoods Village. This newest location will provide patients living in the north Houston area ...
(Date:3/23/2017)... ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the contributions of ... had a significant impact on the careers of all others involved. , On ... inducted into the MBI’s Hall of Fame. The induction took place during the World ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
(Date:3/23/2017)... in St. Joseph, Missouri , has selected AccuReg to help standardize ... 22 cities, and its flagship St. Joseph Medical Center. Mosaic Life Care ... to its patients, including the insurance, billing and collections processes. ... ... Joseph Medical Center ...
(Date:3/23/2017)... 2017 Executive Summary ... extensive primary research (inputs from industry experts, companies, ... present the analysis of global heart valve devices ... Repair); Replacement Procedure By Technique (Mechanical, Bioprosthetic, Transcatheter ... Devices, Balloon Valvuloplasty, Transcatheter Mitral Valve Repair (TMVR)), ...
Breaking Medicine Technology: